Market reviews 2009

Market review on human pharmaceuticals 2009

Published on 9 February 2010

Finland is the most important individual market for Orion, generating about one-third of the Group’s net sales. According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in 2009 totalled EUR 1,947.3 million, down by 0.5% on the previous year. In terms of the number of packages, overall sales were down by 2.3%. Total pharmacy sales were down by 0.9%, while hospital sales were correspondingly up by 0.9%. The wholesale of prescription drugs in the whole market was down by 0.9% and wholesale of self-care products up by 3.0%. According to Statistics Finland, pharmaceutical prices in Finland decreased by 3.6% in 2009.

Orion continued to strengthen its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data, Orion’s wholesale of pharmaceuticals in Finland in 2009 amounted to EUR 186.0 million, up by 3.2% on the previous year. Orion’s sales grew slightly, even though the reference price system implemented in April reduced the overall market. Orion’s market share was 9.6% (9.2%), which was 2.5 percentage points higher than the second-largest company’s market share.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for approximately one-third of the Group’s net sales. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2009 the total sales of Parkinson’s drugs in the United States came to USD 981 million (USD 1,057 million in the previous 12-month period), which is 7.2% less than in the comparative period. The rapid change in the market trend was caused by the expiry of the patent for the leading product, a dopamine agonist, and the resulting competition from generic products.

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in September totalled EUR 895 (852) million, and the average market growth was 5.1%.

Sales of Orion’s Parkinson’s drugs continued to grow clearly faster than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2009, sales of Orion’s Parkinson’s drugs were up by 15.3% at EUR 492 million (EUR 427 million in the previous 12-month period).

 

Published on 26 October 2009

Finland is the most important market for Orion, generating just under one-third of Orion’s net sales. According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–September 2009 totalled EUR 1 433.9 million, down by 0.2% on the comparative period. In terms of the number of packages, overall sales were down by 2.5%. Total pharmacy sales were similar to the comparative period, while hospital sales were up by 0.8%. The wholesale of prescription drugs in the whole market was down by 0.1% and wholesale of self-care products up by 2.7%.

Orion continued to strengthen its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of pharmaceuticals in Finland in January–September 2009 amounted to EUR 137.2 million, up by 4.0% on the comparative period. Orion’s sales clearly grew, even though the overall market remained almost unchanged on the comparative period. Orion’s market share was 9.6% (9.4%), which was 2.6 percentage points higher than the second-largest company’s market share.

Globally, the most important individual therapy area for Orion is the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for approximately one-third of the Group’s net sales. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2009 the total sales of Parkinson’s drugs to retail distributors in the United States came to USD 945 million (USD 1,096 million in the previous 12-month period), which is 14% less than in the comparative period. The rapid change in the market trend was caused by the expiry of the patent for the leading product, a dopamine agonist, and the resulting competition created by the launch of generic products. The five largest European markets for Parkinson’s drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs to retail distributors in the 12-month period ending in June totalled EUR 885 (834) million, and the average market growth was 6%.

Sales of Orion’s Parkinson’s drugs continued to grow clearly faster than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2009, sales of Orion’s Parkinson’s drugs to retail distributors were up by 13% at EUR 415 million (EUR 367 million in the previous 12-month period). In addition, hospital sales of Orion’s Parkinson’s drugs amounted to EUR 59 million. In the United States, sales of Orion’s Parkinson’s drugs to retail distributors in the 12-month period ending in June were USD 166 (149) million, up by 11% on the comparative period. The market share of Orion’s Parkinson’s drugs in the United States was about 17%. In the five largest Parkinson’s drugs markets in Europe, sales of Orion’s Parkinson’s drugs to retail distributors in the 12-month period ending in June totalled EUR 145 (135) million, up by 7% on the comparative period. Orion’s Parkinson’s drugs have an average market share of about 16% in these five markets.

 

Published 7 August 2009

Finland is the most important market for Orion, and it generates just under one-third of Orion’s net sales. According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesales of human pharmaceuticals in the first half of 2009 totalled EUR 959.9 million, which was at the same level as in the comparative period last year. In terms of the number of packages, overall sales fell by 6.7%. Total pharmacy sales rose by 0.6%, while hospital sales fell by 0.9%. The wholesales of prescription drugs grew by 0.1% and the wholesales of self-care products by 1.2%.

Orion continued to strengthen its position as the leading marketer of pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesales of pharmaceuticals in Finland in January–June 2009 amounted to EUR 91.2 million, up by 3.0% year-on-year. Orion’s sales grew slightly, while the overall market remained nearly unchanged from the comparative period. The development of Orion’s sales was supported by the continuously updated product portfolio. Orion’s market share was 9.5% (9.4%), which was 2.4 percentage points higher than that of the second largest marketer.

Globally, the most important indication for Orion is the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for approximately one-third of the Group’s net sales. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March the total sales of Parkinson’s drugs to retail distributors in the United States came to USD 966 million (USD 1,083 million in the previous 12-month period), down by 11% year-on-year. The rapid change in market trends was caused by the expiry of the patent for the leading product, a dopamine agonist, and the resulting competition created by the launch of generic products. The five largest European markets for Parkinson’s drugs were Germany, the UK, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs to retail distributors in the 12-month period ending in March totalled EUR 877 (818) million, and the average market growth was 7%.

The sales of Orion’s Parkinson’s drugs continued to develop favourably, at a clearly higher rate than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2009 the sales of Orion’s Parkinson’s drugs to retail distributors totalled EUR 402 million (EUR 359 million in the previous 12-month period), up by 12%. In addition, the hospital sales of Orion’s Parkinson’s drugs came to EUR 56 million, up by 28% compared to the previous 12-month period. In the United States, the sales of Orion’s Parkinson’s drugs to retail distributors in the 12-month period ending in March were USD 163 (144) million, up by 13% year-on-year. The market share of Orion’s Parkinson’s drugs in the United States was about 17%. In the five largest Parkinson’s drugs markets in Europe, the wholesales of Orion’s Parkinson’s drugs in the 12-month period ending in March totalled EUR 143 (132) million, up by 8% on the comparative period. Orion’s Parkinson’s drugs have an average market share of about 16% in these five markets.

 

Published 27 April 2009

Finland is the most important market area for Orion. According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesales of human pharmaceuticals in the first quarter of 2009 totalled EUR 466.3 million, down by 1.1% on the comparative period last year. With regard to the number of packages sold, overall sales fell by 6.7%. Total pharmacy sales fell by 0.4% and hospital sales by 3.3%. The wholesales of prescription drugs decreased by 1.3%, while the wholesales of self-care products grew by 0.5%.

Orion continued to strengthen its position as the leading marketer of pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s Finnish wholesales of human pharmaceuticals in January–March 2009 totalled EUR 45.2 million, up by 0.4%. Orion’s sales grew slightly, while the overall market decreased. The development of Orion’s sales was supported by the continuously renewed product portfolio. Orion’s market share was 9.7% (9.6%), and 2.3 percentage units higher than that of the second largest marketer. Orion’s market position is further strengthened by the company’s extensive self-care product portfolio and rapid renewal of the generic product portfolio.

According to IMS Health pharmaceutical sales statistics, in 2008 the retail sales of Parkinson’s disease drugs in the USA totalled USD 1,046 (1,051) million, down by 0.5% year-on-year. A year earlier the corresponding growth rate was 27%. The distinct slowdown in market growth was caused by the expiry of the patent for the leading product, a dopamine agonist, and the resulting generic competition. The five largest European markets for Parkinson’s disease drugs were Germany, Great Britain, France, Spain and Italy. Retail sales of Parkinson’s drugs in these countries in 2008 came to EUR 869 (804) million, with an average market growth of about 8.1%.

The sales of Orion’s Parkinson’s disease drugs continued to develop favourably, at a clearly higher rate than the overall market. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2008 the sales of Orion’s Parkinson’s disease drugs totalled EUR 461 million (EUR 428 million in 2007). The wholesales of Orion’s Parkinson’s disease drugs in the USA totalled USD 200.1 (177.4) million, up by 12.8% on the previous year. In the USA, the market share of Orion’s Parkinson’s drugs is about 16%. In the five largest Parkinson’s drug markets in Europe, the wholesales of Orion’s Parkinson’s Disease drugs in 2008 totalled EUR 146.1 (133.5) million, up 9.4% year-on-year. Orion’s Parkinson’s disease drugs have an average market share of about 16% in these five markets.